[8-K] Clearside Biomedical, Inc. Reports Material Event
Clearside Biomedical, Inc. disclosed that Nasdaq notified the company it was non-compliant with the exchange's minimum bid price rule because the company's common stock traded below $1.00 per share for the prior 30 consecutive business days. The company failed to regain compliance within the standard 180‑calendar day cure period ending on
Clearside Biomedical, Inc. ha comunicato che Nasdaq l'ha informata che la società non è conforme alla regola sul prezzo minimo di offerta dell'exchange, poiché le sue azioni ordinarie sono scambiate al di sotto di $1.00 per azione nelle ultime 30 sedute lavorative consecutive. La società non è riuscita a ripristinare la conformità entro il periodo di correzione standard di 180 giorni di calendario che termina il
Clearside Biomedical, Inc. comunicó que Nasdaq informó a la empresa que no cumplía con la regla de precio mínimo de oferta de la bolsa porque sus acciones ordinarias se negociaron por debajo de $1.00 por acción durante los 30 días hábiles consecutivos anteriores. La compañía no logró recuperar el cumplimiento dentro del periodo de cure estándar de 180 días naturales que termina el
Clearside Biomedical, Inc.가 Nasdaq가 회사에 보통주가 거래소의 최저 매수 가격 규정을 위반했다고 통지했다며, 보통주가 $1.00 미만으로 연속된 30영업일 동안 거래되었기 때문이라고 밝혔다. 회사는
Clearside Biomedical, Inc. a annoncé que Nasdaq a informé la société qu'elle n'était pas conforme à la règle relative au prix d'offre minimum de l'échange, car ses actions ordinaires se négociaient en dessous de $1.00 par action au cours des 30 derniers jours ouvrables consécutifs. La société n'a pas réussi à rétablir la conformité dans la période standard de 180 jours calendaires qui se termine le
Clearside Biomedical, Inc. hat bekannt gegeben, dass Nasdaq das Unternehmen darüber informiert hat, dass es nicht mit der Mindestpreis-Regel der Börse übereinstimmt, weil die Stammaktien des Unternehmens in den vorangegangenen 30 Handelstagen ununterbrochen unter $1.00 pro Aktie gehandelt wurden. Das Unternehmen konnte die Konformität innerhalb des standardmäßigen 180-Tage-Kalendertage-Korridors bis zum
Clearside Biomedical, Inc. كشفت أن Nasdaq أبلغت الشركة بأنها غير متوافقة مع قاعدة السعر الأدنى للطرح في البورصة لأن الأسهم العادية للشركة تم تداولها دون $1.00 للسهم لمدة 30 يوماً عملياً متتالية سابقة. فشلت الشركة في استعادة الامتثال ضمن فترة الإصلاح القياسية التي تبلغ 180 يوماً من أيام التقويم المنتهية في
Clearside Biomedical, Inc. 披露称 纳斯达克 已通知公司，由于公司的普通股在前 30 个连续交易日的交易价格低于 $1.00，公司未符合交易所的最低买入价规则。该公司未能在结束于
- Disclosure provided to the market, ensuring regulatory transparency
- Company retained the full 180‑calendar day cure period before Nasdaq escalation
- Non‑compliance with Nasdaq Listing Rule 5450(a)(1) due to sub‑$1 trading for 30 consecutive business days
- Failed to regain compliance by
August 6, 2025 , leading to a delisting notice datedAugust 11, 2025 - Securities are subject to delisting absent a timely hearing or corrective action
Insights
Nasdaq issued a delisting notice after a prolonged sub‑$1 bid price.
The company failed to meet the Minimum Bid Price Requirement because the common stock closed under $1.00 for 30 consecutive business days, triggering the standard 180‑calendar day compliance period. Because the cure period expired on
This puts continued listing at risk unless a hearing is requested; expect potential outcomes over the next weeks depending on whether a timely hearing or plan to regain compliance is submitted.
Disclosure of the notice is a routine governance step but signals elevated listing risk.
Publicly reporting the Nasdaq notice meets disclosure obligations and keeps shareholders informed. The notice itself does not declare a delisting final outcome but indicates the company must act to avoid removal.
Near term, shareholders should watch for a formal hearing request, a board-approved plan to regain compliance, or alternative listing actions; timing is likely in the coming weeks.
Clearside Biomedical, Inc. ha comunicato che Nasdaq l'ha informata che la società non è conforme alla regola sul prezzo minimo di offerta dell'exchange, poiché le sue azioni ordinarie sono scambiate al di sotto di $1.00 per azione nelle ultime 30 sedute lavorative consecutive. La società non è riuscita a ripristinare la conformità entro il periodo di correzione standard di 180 giorni di calendario che termina il
Clearside Biomedical, Inc. comunicó que Nasdaq informó a la empresa que no cumplía con la regla de precio mínimo de oferta de la bolsa porque sus acciones ordinarias se negociaron por debajo de $1.00 por acción durante los 30 días hábiles consecutivos anteriores. La compañía no logró recuperar el cumplimiento dentro del periodo de cure estándar de 180 días naturales que termina el
Clearside Biomedical, Inc.가 Nasdaq가 회사에 보통주가 거래소의 최저 매수 가격 규정을 위반했다고 통지했다며, 보통주가 $1.00 미만으로 연속된 30영업일 동안 거래되었기 때문이라고 밝혔다. 회사는
Clearside Biomedical, Inc. a annoncé que Nasdaq a informé la société qu'elle n'était pas conforme à la règle relative au prix d'offre minimum de l'échange, car ses actions ordinaires se négociaient en dessous de $1.00 par action au cours des 30 derniers jours ouvrables consécutifs. La société n'a pas réussi à rétablir la conformité dans la période standard de 180 jours calendaires qui se termine le
Clearside Biomedical, Inc. hat bekannt gegeben, dass Nasdaq das Unternehmen darüber informiert hat, dass es nicht mit der Mindestpreis-Regel der Börse übereinstimmt, weil die Stammaktien des Unternehmens in den vorangegangenen 30 Handelstagen ununterbrochen unter $1.00 pro Aktie gehandelt wurden. Das Unternehmen konnte die Konformität innerhalb des standardmäßigen 180-Tage-Kalendertage-Korridors bis zum
FAQ
What did Clearside Biomedical (CLSD) disclose about Nasdaq compliance?
When did the 180‑day compliance period end for CLSD?
What action did Nasdaq take after the cure period expired?
Does the notice mean CLSD is already delisted?
What are the near‑term items investors should expect?
